Artículo

Pharmacological treatment and vaccines in monkeypox virus: a narrative review and bibliometric analysis

Resumen

Mpox (earlier known as monkeypox) virus infection is a recognized public health emergency. There has been little research on the treatment options. This article reviews the specific drugs used to treat mpox virus infection and the vaccines used here. Instead of focusing on the mechanistic basis, this review narrates the practical, real-life experiences of individual patients of mpox virus disease being administered these medicines. We conducted a bibliometric analysis on the treatment of the mpox virus using data from several databases like PubMed, Scopus, and Embase. The research on this topic has grown tremendously recently but it is highly concentrated in a few countries. Cidofovir is the most studied drug. This is because it is indicated and also used off-label for several conditions. The drugs used for mpox virus infection include tecovirimat, cidofovir, brincidofovir, vaccinia immune globulin, and trifluridine. Tecovirimat is used most frequently. It is a promising option in progressive mpox disease in terms of both efficacy and safety. Brincidofovir has been associated with treatment discontinuation due to elevated hepatic enzymes. Cidofovir is also not the preferred drug, often used because of the unavailability of tecovirimat. Trifluridine is used topically as an add-on agent along with tecovirimat for ocular manifestations of mpox virus disease. No study reports individual patient data for vaccinia immune globulin. Though no vaccine is currently approved for mpox virus infection, ACAM 2000 and JYNNEOS are the vaccines being mainly considered. ACAM 2000 is capable of replicating and may cause severe adverse reactions. It is used when JYNNEOS is contraindicated. Several drugs and vaccines are under development and have been discussed alongside pragmatic aspects of mpox virus treatment and prevention. Further studies can provide more insight into the safety and efficacy of Tecovirimat in actively progressing mpox virus disease.
Autores
Shamim, MA; Satapathy, P; Padhi, BK; Veeramachaneni, SD; Akhtar, N; Pradhan, A; Agrawal, A; Dwivedi, P; Mohanty, A; Pradhan, KB; Kabir, R; Rabaan, AA; Alotaibi, J; Al Ismail, ZA; Alsoliabi, ZA; Al Fraij, A; Sah, R; Rodriguez-Morales, AJ
Título
Pharmacological treatment and vaccines in monkeypox virus: a narrative review and bibliometric analysis
Afiliaciones
All India Institute of Medical Sciences (AIIMS) Jodhpur; Post Graduate Institute of Medical Education & Research (PGIMER), Chandigarh; Post Graduate Institute of Medical Education & Research (PGIMER), Chandigarh; Indian Council of Medical Research (ICMR); ICMR – Regional Medical Research Centre (RMRC), Bhubaneswar; All India Institute of Medical Sciences (AIIMS) Jodhpur; Chitkara University, Punjab; Anglia Ruskin University; Johns Hopkins University; Johns Hopkins Medicine; King Faisal Specialist Hospital & Research Center; Qatif Central Hospital; Tribhuvan University; Institute of Medicine (IoM) – Nepal; Harvard University; Harvard Medical School; Dr DY Patil Vidyapeeth Pune; Dr D Y Patil Medical College, Hospital & Research Centre; Universidad Cientifica del Sur (CIENTIFICA); Lebanese American University
Año
2023
DOI
10.3389/fphar.2023.1149909
Tipo de acceso abierto
Green Accepted, gold, Green Published
Referencia
WOS:000992052500001
Artículo obtenido de:
WOS
Fuente
0 0 votos
Califica el artículo
Subscribirse
Notificación de
Campus Samborondón
Vía Samborondón Km. 13.5
Call Center: 5150400
metricas@ecotec.edu.ec
Facebook Instagram Youtube

Mapa del sitio